Mustang Bio, Inc. (MBIO)
Chart Events
Performance Outlook
| Previous Close | 2.3200 |
| Open | 2.2200 |
| Bid | 2.3500 x 4000 |
| Ask | 2.4100 x 1200 |
| Day's Range | 2.2200 - 2.4000 |
| 52 Week Range | 2.2000 - 11.0850 |
| Volume | |
| Avg. Volume | 30,928 |
| Market Cap | 19.527M |
| Beta (5Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.0700 |
| Earnings Date | Nov 13, 2023 - Nov 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MBIO
Related Research
- Mustang Bio, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat3 years agoMorningstar
GlobeNewswireMustang Bio to Participate in Upcoming September 2023 Investor Conferences
WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City. Details of the events are as follows: H.C. W
- GlobeNewswire
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy Aligns with ongoing results from investigator-sponsored trial at Fred Hutch that show ongoing complete remission for more than three years Update on data presented at 5th iwCAR-T, Scottsdale, AZ Safety Review Committee unanimously approved dose escalation of the indolent lymphoma arm WORCESTER, Mass., Aug. 16
- GlobeNewswire
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “In the sec
